During the past decade, Instituto Médico DAMIC conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 10 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 5 clinical trials were completed. i.e. 35.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Médico DAMIC" #1 sponsor was "Boehringer Ingelheim" with 6 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Amgen" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Médico DAMIC" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "ARTTIC International Management Services" with 1 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "Federación Argentina de Cardiología FAC" with 1 trials as a collaborator and "Ferrer Internacional S.A." with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Médico DAMIC" are "Depressive Disorder, Major" (5 trials), "Heart Failure" (3 trials), "Cardiovascular Disease" (2 trials), "Schizophrenia" (2 trials) and "Ulcerative Colitis" (2 trials). Many other conditions were trialed in "Instituto Médico DAMIC" in a lesser frequency.

Most popular intervention types in "Instituto Médico DAMIC" are "Drug" (25 trials), "Other" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Aticaprant" (2 trials), "Empagliflozin" (2 trials), "Etrolizumab" (2 trials) and "Rituximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Médico DAMIC" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Instituto Médico DAMIC". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Instituto Médico DAMIC, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Médico DAMIC, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".